Our results indicate that cachexia prevention by sunitinib is mainly determined by the reduction of proteolysis, rather than increased synthesis, as shown by suppression of MuRF-1 and, though less evident, atrogin-1 induction and unchanged levels of p-AKT/AKT ratio. The gene discussed is AKT1; the disease is Cachexia.